Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 53
Filter
1.
Nat Commun ; 14(1): 4072, 2023 07 10.
Article in English | MEDLINE | ID: mdl-37429857

ABSTRACT

The CRISPR-Cas9 system has revolutionized our ability to precisely modify the genome and has led to gene editing in clinical applications. Comprehensive analysis of gene editing products at the targeted cut-site has revealed a complex spectrum of outcomes. ON-target genotoxicity is underestimated with standard PCR-based methods and necessitates appropriate and more sensitive detection methods. Here, we present two complementary Fluorescence-Assisted Megabase-scale Rearrangements Detection (FAMReD) systems that enable the detection, quantification, and cell sorting of edited cells with megabase-scale loss of heterozygosity (LOH). These tools reveal rare complex chromosomal rearrangements caused by Cas9-nuclease and show that LOH frequency depends on cell division rate during editing and p53 status. Cell cycle arrest during editing suppresses the occurrence of LOH without compromising editing. These data are confirmed in human stem/progenitor cells, suggesting that clinical trials should consider p53 status and cell proliferation rate during editing to limit this risk by designing safer protocols.


Subject(s)
CRISPR-Cas Systems , Tumor Suppressor Protein p53 , Humans , CRISPR-Cas Systems/genetics , Tumor Suppressor Protein p53/genetics , Cell Cycle Checkpoints/genetics , Cell Division , Cell Separation , RNA
2.
Nat Commun ; 12(1): 4922, 2021 08 13.
Article in English | MEDLINE | ID: mdl-34389729

ABSTRACT

CRISPR-Cas9 is a promising technology for gene therapy. However, the ON-target genotoxicity of CRISPR-Cas9 nuclease due to DNA double-strand breaks has received little attention and is probably underestimated. Here we report that genome editing targeting globin genes induces megabase-scale losses of heterozygosity (LOH) from the globin CRISPR-Cas9 cut-site to the telomere (5.2 Mb). In established lines, CRISPR-Cas9 nuclease induces frequent terminal chromosome 11p truncations and rare copy-neutral LOH. In primary hematopoietic progenitor/stem cells, we detect 1.1% of clones (7/648) with acquired megabase LOH induced by CRISPR-Cas9. In-depth analysis by SNP-array reveals the presence of copy-neutral LOH. This leads to 11p15.5 partial uniparental disomy, comprising two Chr11p15.5 imprinting centers (H19/IGF2:IG-DMR/IC1 and KCNQ1OT1:TSS-DMR/IC2) and impacting H19 and IGF2 expression. While this genotoxicity is a safety concern for CRISPR clinical trials, it is also an opportunity to model copy-neutral-LOH for genetic diseases and cancers.


Subject(s)
CRISPR-Cas Systems , Gene Editing/methods , Globins/genetics , Hematopoietic Stem Cells/metabolism , Loss of Heterozygosity/genetics , Sequence Deletion , Cells, Cultured , Chromosome Deletion , Chromosomes, Human, Pair 11/genetics , DNA Methylation , Gene Expression , HEK293 Cells , Hematopoietic Stem Cells/cytology , Humans , Insulin-Like Growth Factor II/genetics , Polymorphism, Single Nucleotide , RNA, Long Noncoding/genetics
3.
J Pharm Biomed Anal ; 49(2): 508-12, 2009 Feb 20.
Article in English | MEDLINE | ID: mdl-19097719

ABSTRACT

A liquid chromatographic method was developed to analyse a tablet containing three anti-human immunodeficiency virus (HIV) compounds: lamivudine, zidovudine and a compound with the code name TMC278.HCl. Due to the presence of UV absorbing chromophores in the three active components, a single LC method with UV detection was developed. A Hypersil BDS C(18) column was used as stationary phase and the assay was performed with gradient elution using mobile phases containing acetonitrile, 0.2M potassium dihydrogen phosphate and water. The sample pretreatment is performed by treating the formulation with dimethyl sulfoxide-water (1:1) followed by filtration. After method development, the influence of the different chromatographic parameters on the separation, the interference of other active compounds and excipients, the repeatability and the linearity were investigated. The method was shown to be robust, selective, linear and repeatable. Finally, the content of the compounds in the tablet was determined.


Subject(s)
Anti-HIV Agents/chemistry , Lamivudine/chemistry , Nitriles/chemistry , Pyrimidines/chemistry , Zidovudine/chemistry , Biological Assay , Calibration , Chemistry, Pharmaceutical , Chromatography, Liquid/methods , HIV/drug effects , Humans , Light , Molecular Structure , Reference Standards , Rilpivirine , Scattering, Radiation , Sensitivity and Specificity , Solvents/chemistry , Spectrophotometry, Ultraviolet/methods , Tablets
4.
Ann Oncol ; 18(5): 909-16, 2007 May.
Article in English | MEDLINE | ID: mdl-17322546

ABSTRACT

BACKGROUND: Acute dysphagia is a distressing dose-limiting toxicity after concurrent chemoradiation or high-dose radiotherapy for lung cancer. We therefore identified factors associated with the occurrence of acute dysphagia in lung cancer patients receiving radiotherapy alone or combined with chemotherapy. PATIENTS AND METHODS: Radiotherapy, chemotherapy and patient characteristics were analyzed using ordinal regression analysis as possible predictors for acute dysphagia (CTCAE 3.0) in 328 lung cancer patients treated with curative intent. RESULTS: The most significant association was seen between the maximal grade of neutropenia during chemoradiation and dysphagia, with an odds ratio increasing from 1.49 [95% confidence interval (CI) 0.63-3.54, P = 0.362] for grade 1-2 neutropenia to 19.7 (95% CI 4.66-83.52, P < 0.001) for patients with grade 4 neutropenia. Twice-daily schedule, mean esophageal dose and administration of chemotherapy were significant predictive factors. By combining these factors, a high-performance predictive model was made. On an individual patient level, 64% of patients were correctly classified and only 1.2% of patients were misclassified by more than one grade. CONCLUSIONS: The maximal neutrophil toxicity during concurrent chemotherapy and radiotherapy is strongly associated with the development of acute dysphagia. A multivariate predictive model was developed.


Subject(s)
Deglutition Disorders/etiology , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Neutropenia/etiology , Radiation Injuries/etiology , Acute Disease , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/radiotherapy , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Radiotherapy Dosage , Retrospective Studies
5.
Nucleosides Nucleotides Nucleic Acids ; 23(8-9): 1425-9, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15571271

ABSTRACT

To explain why 2-chloro-2'-deoxyadenosine (CdA) is unable to block DNA synthesis and cell cycle progression, and paradoxically enhances progression from G1 into S phase in the CdA-resistant leukemia EHEB cell line, we studied its metabolism and effects on proteins regulating the transition from G1 to S phase. A low deoxycytidine kinase activity and CdATP accumulation, and a lack of p21 induction despite p53 phosphorylation and accumulation may account for the inability of CdA to block the cell cycle. An alternative pathway involving pRb phosphorylation seems implicated in the CdA-induced increase in G1 to S phase progression.


Subject(s)
Cladribine/pharmacology , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Antimetabolites, Antineoplastic/pharmacology , Antineoplastic Agents/pharmacology , Blotting, Western , Bromodeoxyuridine/pharmacology , Cell Cycle , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Chromatography, High Pressure Liquid , Cyclin-Dependent Kinase Inhibitor p21 , DNA/biosynthesis , DNA/metabolism , Deoxycytidine Kinase/metabolism , Dose-Response Relationship, Drug , Enzyme Inhibitors/metabolism , Flow Cytometry , G1 Phase , Humans , Inhibitory Concentration 50 , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Models, Biological , Phosphorylation , S Phase , Time Factors
6.
Leukemia ; 16(1): 36-43, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11840261

ABSTRACT

2-Chloro-2'-deoxyadenosine (CdA) is a deoxyadenosine analogue which targets enzymes involved in DNA synthesis, and hence might interfere with the resynthesis step of DNA repair. We tested this hypothesis in resting B cell chronic lymphocytic leukemia (B-CLL) lymphocytes, after firstly characterizing unscheduled DNA synthesis occurring in these cells. We observed that the spontaneous incorporation of [methyl-3H]thymidine (dThd) into DNA of B-CLL cells was not completely inhibitable by hydroxyurea (HU) which blocks DNA replication. In addition, in the presence of HU, dThd incorporation could be upregulated by UVC radiation or DNA alkylation, without re-entry of the cells into S phase. CdA was found to inhibit both spontaneous and upregulated DNA synthesis in B-CLL cells. Phosphorylation of CdA was essential to exert this effect. We finally observed a strong synergistic cytotoxicity between UV light and CdA, which was correlated with activation of caspase-3 and high molecular weight DNA fragmentation, two markers of apoptosis. Taken together, these observations indicate that in B-CLL cells CdA inhibits unscheduled DNA synthesis which represents the polymerizing step of a repair process responsive to DNA aggression. Inhibition of this process by CdA, together with a combined activation of the apoptotic proteolytic cascade by CdA and UV, may explain their synergistic cytotoxicity.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , B-Lymphocytes/drug effects , Cladribine/pharmacology , DNA Repair/drug effects , DNA Replication/drug effects , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Neoplastic Stem Cells/drug effects , Prodrugs/pharmacology , Radiation-Sensitizing Agents/pharmacology , Alkylating Agents/pharmacology , Alkylation , Antimetabolites, Antineoplastic/metabolism , Apoptosis/drug effects , Apoptosis/radiation effects , B-Lymphocytes/metabolism , B-Lymphocytes/radiation effects , Caspase 3 , Caspases/analysis , Cladribine/metabolism , DNA Damage , DNA, Neoplasm/biosynthesis , DNA, Neoplasm/drug effects , DNA, Neoplasm/radiation effects , Depression, Chemical , Humans , Hydroxyurea/pharmacology , Neoplasm Proteins/analysis , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/radiation effects , Phosphorylation , Prodrugs/metabolism , Radiation Tolerance , Thymidine/metabolism , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Tumor Cells, Cultured/radiation effects , Ultraviolet Rays
7.
Drug Dev Ind Pharm ; 27(8): 885-92, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11699842

ABSTRACT

A novel bending point criterion was developed and compared with a number of existing criteria for the interpretation of certain dissolution profiles; these comparison criteria were the percentage dissolved at a fixed time point, the fitted Weibull parameters, and the area under the dissolution curve (AUC). The statistical bending point model was applied to dissolution curves that showed linear dissolution. The bending point model is based on a general linear model, and its confidence information is obtained using the variance-covariance matrix of the parameter estimates. Practically, three time points in the linear part and two time points on the plateau level are used for a reliable bending point estimation. A comparative study with three batches and three storage conditions of slow-release mucoadhesive buccal tablets was performed. The relative standard deviation (RSD) values of the bending point were typically between 1% and 5% which are considerably lower than the corresponding values of the other criteria (typically between 3% and 15%). The bending point criterion is considered robust and stable for the characterization of certain dissolution profiles. Moreover, the bending point has a particular physical interpretation that is helpful in the framework of the slow-release application of this buccal tablet.


Subject(s)
Solubility , Adhesives , Algorithms , Data Interpretation, Statistical , Delayed-Action Preparations , Drug Stability , Drug Storage , Kinetics , Models, Statistical , Tablets , Temperature
8.
Clin Cancer Res ; 7(11): 3559-66, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11705877

ABSTRACT

The effects of 2-chloro-2'-deoxyadenosine (CdA, cladribine), an adenosine deaminase-resistant analogue toxic for both proliferating and resting lymphoid cells, were investigated in the human leukemia cell line EHEB, which was derived from a patient with B-cell chronic lymphocytic leukemia. These cells were found to be less sensitive to CdA than B-cell chronic lymphocytic leukemia lymphocytes (approximately 25-fold) and other human lymphoblastic cell lines (10-1000-fold). Phosphorylation of CdA by deoxycytidine kinase and intracellular accumulation of 2-chloro-2'-deoxyadenosine triphosphate (CdATP) were similar in EHEB cells and in other CdA-sensitive cell lines. In contrast, the inhibitory effect of CdA on ribonucleotide reductase activity, which was investigated in situ by the conversion of cytidine into deoxyribonucleotides and its incorporation into DNA, was much less pronounced in EHEB cells than in other human lymphoblastic cells. Accordingly, concentrations of deoxynucleoside triphosphates did not decrease and even tended to rise. Unexpectedly, incorporation of thymidine and deoxycytidine into DNA was increased severalfold after a 24-h incubation with CdA. CdA also increased the activities of deoxycytidine kinase and thymidine kinase approximately 4-fold. Analysis of the cell cycle by flow cytometry showed that after 24 h, CdA provoked an increase in the proportion of cells in S phase, synthesizing DNA. We conclude that the EHEB cell line is resistant to the cytotoxic action of CdA not only because of a lack of inhibition of ribonucleotide reduction but also because CdA, in contrast with its known effects, provokes in this cell line an increase in the proportion of cells replicating their DNA. Unraveling of the mechanism of this effect may shed light on clinical resistance to CdA.


Subject(s)
Antineoplastic Agents/pharmacology , Cladribine/pharmacology , Leukemia, B-Cell/pathology , Cell Cycle/drug effects , Cell Cycle/physiology , Cell Survival/drug effects , Cladribine/metabolism , Cytidine/metabolism , DNA, Neoplasm/drug effects , DNA, Neoplasm/metabolism , Deoxycytidine/metabolism , Deoxycytidine Kinase/drug effects , Deoxycytidine Kinase/metabolism , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm , Humans , Inhibitory Concentration 50 , Leukemia, B-Cell/drug therapy , Leukemia, B-Cell/metabolism , Nucleotides/metabolism , Phosphorylation , Ribonucleotide Reductases/drug effects , Ribonucleotide Reductases/metabolism , Thymidine Kinase/drug effects , Thymidine Kinase/metabolism , Tumor Cells, Cultured
9.
Radiother Oncol ; 61(2): 177-84, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11690684

ABSTRACT

BACKGROUND AND PURPOSE: To determine the influence of the number of fractions (or the dose per fraction) on the proton relative biological effectiveness (RBE). MATERIALS AND METHODS: Intestinal crypt regeneration in mice was used as the biological endpoint. RBE was determined relative to cobalt-60 gamma rays for irradiations in one, three and ten fractions separated by a time interval of 3.5h. Proton irradiations were performed at the middle of a 7-cm Spread Out Bragg Peak (SOBP). RESULTS: Proton RBEs (and corresponding gamma dose per fraction) at the level of 20 regenerated crypts per circumference were found equal to 1.15+/-0.04 (10.0 Gy), 1.15+/-0.05 (4.8 Gy) and 1.14+/-0.07 (1.7 Gy) for irradiations in one, three and ten fractions, respectively. Alpha/beta ratios as derived from direct analysis of the 'quantal radiation response data' were found to be 7.6 Gy for gamma rays and 8.2 Gy for protons. Additional proton irradiations in ten fractions at the end of the SOBP were found to be more effective than at the middle of the SOBP by a factor of 1.14 (1.05-1.23). CONCLUSION: Proton RBE for crypt regeneration was found to be independent of fractionation up to ten fractions. One can expect that it remains unchanged for higher number of fractions as the lethalities for doses smaller than 3 Gy are exclusively due to direct lethal events. As a tendency for increased effectiveness at the end of the SOBP is reported in the majority of the studies, for clinical applications it would be advisable to allow for by arranging a sloping depth dose curve in the deeper part of the target volume. Finally, it must be noticed that most of in vitro and in vivo RBE values for protons are larger than the current clinical RBE (RBE=1.10).


Subject(s)
Dose Fractionation, Radiation , Intestines/radiation effects , Radiation Tolerance , Animals , Female , Gamma Rays , Intestines/pathology , Intestines/physiology , Male , Mice , Mice, Inbred BALB C , Protons , Radiotherapy, High-Energy , Random Allocation , Regeneration , Whole-Body Irradiation
10.
Ann Oncol ; 10(9): 1051-7, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10572602

ABSTRACT

BACKGROUND: The role of chemotherapy dose-intensification in small-cell lung cancer (SCLC) remains unclear. This phase I-II study evaluates feasibility and outcome of combination chemotherapy at moderately elevated doses with concomitant thoracic radiotherapy in limited-disease SCLC. PATIENTS AND METHODS: Moderately elevated doses of ifosfamide-epirubicin (cycles 1 and 3) and of carboplatin-etoposide (cycles 2 and 4) were given with G-CSF and peripheral blood stem-cell (PBSC) support. Thoracic radiotherapy (40 Gy) was given once daily during the first five days of each cycle. RESULTS: Overall toxicity was acceptable; most common side-effects were myelosuppression and asthenia. All 35 eligible patients responded (23 CR, 12 PR). Median time to progression was 15 months: median overall survival was 24.6 months. Only 6 of 25 relapsing patients (24%) presented with a locoregional recurrence while 12 of 25 (48%) relapsed in the central nervous system (CNS). CONCLUSIONS: This regimen is a feasible dose-intensification with an acceptable toxicity profile. Its efficacy was demonstrated by a 100% response rate, an excellent local tumor control rate and a median survival of 24.6 months. In the absence of PCI, CNS relapse is a major problem if adequate local control is achieved.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/radiotherapy , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Aged , Carboplatin/administration & dosage , Carcinoma, Small Cell/mortality , Combined Modality Therapy , Epirubicin/administration & dosage , Etoposide/administration & dosage , Female , Follow-Up Studies , Granulocyte Colony-Stimulating Factor/administration & dosage , Humans , Ifosfamide/administration & dosage , Lung Neoplasms/mortality , Male , Middle Aged , Nervous System Neoplasms/secondary , Neutropenia/chemically induced , Recurrence , Survival Rate , Thoracic Neoplasms/radiotherapy , Thrombocytopenia/chemically induced , Treatment Outcome
11.
Oncol Rep ; 6(5): 949-57, 1999.
Article in English | MEDLINE | ID: mdl-10425285

ABSTRACT

The available knowledge on potential radiosensitizing nucleoside analogues with special focus on fludarabine and gemcitabine is reviewed. These analogues are prodrugs whose active triphosphate forms inhibit various enzymes involved in DNA synthesis and repair. Several properties of these analogues support their use as radiosensitizers. As repair inhibitors, they have the potential to increase the amount of residual DNA and chromosome damage after irradiation, and as DNA synthesis inhibitors, they specifically target the S-phase cell component and could thus overcome the detrimental effect of tumor clonogen repopulation during fractionated irradiation. Also, through their cytotoxic effect, these analogues could increase tumor cell loss, facilitating tumor reoxygenation, and thus obviate tumor hypoxia's inhibitory effect on radioresponse. Induction of DNA damage in all phases of the cell cycle by irradiation could create DNA sites for drug incorporation, possibly inducing an apoptotic response in cells outside of S-phase. Experimental data addressing these hypotheses are reviewed and updates on ongoing clinical trials combining fludarabine or gemcitabine and irradiation are given.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms/drug therapy , Neoplasms/radiotherapy , Nucleosides/therapeutic use , Prodrugs/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Deoxycytidine/analogs & derivatives , Deoxycytidine/therapeutic use , Humans , Nucleosides/chemistry , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use , Gemcitabine
12.
Int J Radiat Biol ; 75(2): 245-51, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10072186

ABSTRACT

PURPOSE: The present study investigated in vitro radio-enhancement by gemcitabine (dFdC) in two head and neck squamous cell carcinomas with different intrinsic cellular radiosensitivity. MATERIALS AND METHODS: Radiosensitive (SCC61, SF2=0.16) and radioresistant (SQD9, SF2=0.49) human head and neck squamous cell carcinomas were used. Confluent cells were incubated with dFdC and irradiated in drug-free medium with a single dose of 250 kV X-rays (0-12Gy). Cell survival curves were corrected for the toxicity of the drug alone. RESULTS: In both cell lines, radio-enhancement was observed with 5 microM dFdC incubated for 3 h prior to irradiation. Dose modification factors (DMF) at a surviving fraction level of 0.5 reached 1.3 (95% CI 1.1-1.6) and 1.5 (95% CI 1.4-1.5) for SQD9 and SCC61 cells, respectively. Radio-enhancement was associated with a modest increase in the alpha term of the linear-quadratic model. In SQD9 cells, radio-enhancement increased with dFdC incubation time. At 24h, DMF reached a value of 1.5 (95% CI 0.9-3.2). In SCC61 cells at 24h, DMF reached a value of 1.1 (95% CI 0.9-1.2). In both cell lines, radio-enhancement increased with dFdC concentration up to 5-10 microM from which values it levelled off up to 100 microM. CONCLUSIONS: The data indicated that dFdC induced a modest radio-enhancement in both cell lines. For a short incubation time, dFdC did not radio-enhance preferentially the more radio-resistant cells, whereas the opposite was observed for a longer time. In both cell lines, radio-enhancement was saturated above a dFdC concentration of 5-10 microM.


Subject(s)
Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Deoxycytidine/analogs & derivatives , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Radiation-Sensitizing Agents/pharmacology , Carcinoma, Squamous Cell/pathology , Cell Death/drug effects , Cell Death/radiation effects , Combined Modality Therapy , Deoxycytidine/pharmacology , Head and Neck Neoplasms/pathology , Humans , Radiation Tolerance , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/radiation effects , Gemcitabine
13.
Radiother Oncol ; 53(1): 1-13, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10624847

ABSTRACT

BACKGROUND AND PURPOSE: A cost minimization analysis of radiotherapy (RT), laser microsurgery (L) or partial laryngectomy (PL), which are equally effective options for T1N0 glottic SCC was carried out from the perspective of the National Health Care System. METHODS: For each modality, the various events associated with the diagnostic procedure, the primary treatment, the complications, and the salvage treatment were individualized. The charges of each of these events weighted for the frequency of occurrence were then determined using the 'fee for service' policy established by the National Health Insurance of Belgium. RESULTS: A total cost of 5172, 5847 and 11563 EURO were calculated for RT, L and PL, respectively. For L, cost included post-operative RT applied in case of positive margins (30%). For PL, the cost of the primary treatment accounted for 68% of the total cost whereas it only accounted for 50 and 43% for L and RT, respectively. For RT, L or PL, complications accounted for less than 10% of the total cost. The cost of salvage treatment reached 19, 14 and 8% of the total cost for RT, L and PL, respectively. A sensitivity analysis indicated that reduction of the duration of hospitalization decreases the costs without affecting the ranking between the three options. Also, the cost of L could be reduced even slightly below the cost of RT by decreasing the need for post-operative RT. CONCLUSIONS: RT and L have almost the same expected average cost for the treatment of T1N0 glottic SCC, whereas PL is twice as expensive.


Subject(s)
Carcinoma, Squamous Cell/economics , Carcinoma, Squamous Cell/therapy , Laryngeal Neoplasms/economics , Laryngeal Neoplasms/therapy , Belgium , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Cost Savings , Glottis , Humans , Laryngeal Neoplasms/pathology , Laryngectomy/economics , Laser Therapy/economics , Length of Stay/economics , Microsurgery/economics , Radiotherapy/economics
14.
Radiother Oncol ; 48(2): 175-83, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9783889

ABSTRACT

PURPOSE: The aim of this study was to retrospectively compare the efficacy and functional results of three treatment options for T1N0M0 glottic carcinomas applied in a single institution. MATERIALS AND METHODS: One hundred six charts of patients with biopsy-proven T1N0M0 glottic carcinomas treated between 1979 and 1995 were reviewed. There were 81 T1a and 25 T1b tumors. Forty-one patients were treated by radiotherapy (RT) (median dose of 64 Gy), 34 patients were treated by partial laryngectomy (PL) and 31 patients were treated by laser microsurgery (L) of which 10 received postoperative RT for positive margins. In 18 patients, a perceptual voice rating on a visual scale was performed by the patients themselves, three non-speech specialists and two speech therapists. RESULTS: With a median follow-up time of 63.5 months, the 5- and 10-year loco-regional control probabilities reached 91 and 87%, respectively, without any difference between the treatment groups. After salvage laryngectomy, the 5- and 10-year loco-regional control probabilities reached 97% without any difference between the treatment groups. For the whole population, overall survival reached 78 and 62.4% at 5 and 10 years, respectively. The actuarial incidence of second primary reached 19% at 10 years. Regarding the quality of voice, overall there was a trend towards a worse satisfaction index, more hoarseness and more breathiness after PL than after L or RT. CONCLUSIONS: Our data suggested that assuming proper selection of patients, RT and L yielded similar outcomes and functional results. Local recurrence can be adequately salvaged by surgery. On the other hand, PL appeared to yield similar loco-regional control probability but with a worse quality of voice.


Subject(s)
Carcinoma/radiotherapy , Glottis/radiation effects , Laryngeal Neoplasms/radiotherapy , Laryngectomy/methods , Laser Therapy/methods , Microsurgery , Actuarial Analysis , Adult , Aged , Aged, 80 and over , Biopsy , Carcinoma/pathology , Carcinoma/surgery , Female , Follow-Up Studies , Glottis/pathology , Glottis/surgery , Hoarseness/etiology , Humans , Laryngeal Neoplasms/pathology , Laryngeal Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Neoplasms, Second Primary/pathology , Patient Satisfaction , Radiotherapy Dosage , Radiotherapy, Adjuvant , Retrospective Studies , Salvage Therapy , Survival Rate , Treatment Outcome , Voice Quality
15.
Br J Cancer ; 76(10): 1315-21, 1997.
Article in English | MEDLINE | ID: mdl-9374377

ABSTRACT

Gemcitabine (dFdC), a deoxycitidine nucleoside analogue, inhibits DNA synthesis and repair of radiation-induced chromosome breaks in vitro, radiosensitizes various human and mouse cells in vitro and shows clinical activity in several tumours. Limited data are however available on the effect of dFdC on normal tissue radiotolerance and on factors associated with dFdC's radiosensitization in vivo. The purpose of this study was to determine the effect of dFdC on mouse jejunum radiosensitization and to investigate the kinetics of DNA synthesis inhibition and cell cycle redistribution in the jejunal crypts as surrogates of radiosensitization in vivo. For assessment of jejunum tolerance, the mice were irradiated on the whole body with 60Co gamma rays (3.5-18 Gy single dose) with or without prior administration of dFdC (150 mg kg-1). Jejunum tolerance was evaluated by the number of regenerated crypts per circumference at 86 h after irradiation. For pharmacodynamic studies, dFdC (150 or 600 mg kg-1) was given i.p. and jejunum was harvested at various times (0-48 h), preceded by a pulse BrdUrd labelling. Labelled cells were detected by immunohistochemistry on paraffin-embedded sections. DNA synthesis was inhibited within 3 h after dFdC administration. After an early wave of apoptosis (3-6 h), DNA synthesis recovered by 6 h, and crypt cells became synchronized. At 48 h, the labelling index returned almost to background level. At a level of 40 regenerated crypts, radiosensitization was observed for a 3 h time interval (dose modification factor of 1.3) and was associated with DNA synthesis inhibition, whereas a slight radioprotection was observed for a 48-h time interval (dose modification factor of 0.9) when DNA synthesis has reinitiated. In conclusion, dFdC altered the radioresponse of the mouse jejunum in a schedule-dependent fashion. Our data tend to support the hypothesis that DNA synthesis inhibition and cell cycle redistribution are surrogates for radiosensitization. More data points are however required before a definite conclusion can be drawn.


Subject(s)
Cell Cycle/drug effects , DNA/biosynthesis , Deoxycytidine/analogs & derivatives , Jejunum/radiation effects , Radiation-Sensitizing Agents/pharmacology , Animals , Deoxycytidine/pharmacology , Kinetics , Male , Mice , Mice, Inbred C3H , Radiation Tolerance , Gemcitabine
16.
Eur J Cardiothorac Surg ; 10(10): 817-25, 1996.
Article in English | MEDLINE | ID: mdl-8911833

ABSTRACT

OBJECTIVE: To assess the risk of ischemic cord injury, we have retrospectively studied the 115 patients who underwent a replacement of the thoracic descending or thoraco-abdominal aorta between January 1980 and December 1994. METHODS: In 72 patients the aortic lesion was located above the diaphragm. The aortic replacement was performed with the aid of extracorporeal circulation in all but 2 patients (97.2%). Only two cases of postoperative paraplegia were observed (2.7%). In 43 patients (10 females and 33 males aged from 26 to 69 years), the occurrence of postoperative paraplegia was considered as a major risk, because of the extension of the aortic lesions (Crawford types I, II and III). Twenty-six patients (60.4%) suffered from chronic dissection and 17 patients had atheromatous aneurysms. Sixteen patients (37.2%) had Marfan syndrome. Twelve patients (27.9%) had already undergone aortic replacement. A preoperative study of the spinal cord vascularization was carried out in 36 patients (83.6%) and the Adamkiewicz artery was visualized in 28 patients (77.8%). In 17 patients (39.5%, group I), the surgical procedure was performed without the aid of extracorporeal circulation. In the remaining 26 patients (60.5%, group II), the surgical procedure was carried out with the aid of cardiopulmonary bypass and profound hypothermic circulatory arrest. Sequential unclamping of the aorta was used in all patients. The cord vascularization was surgically restored in 32 patients (74.4%). When the Adamkiewicz artery was identified, the critical intercostal artery was reimplanted together with the two pairs of adjacent intercostal arteries (25 patients). When the origin of the Adamkiewicz artery remained unknown, the two or three most important patent pairs of intercostal arteries were reimplanted (7 patients). In 8 patients (18.6%) there were no patent intercostal arteries. RESULTS: Hospital mortality accounted for 37.2% (16 patients, including 5 patients with paraplegia). On univariate analysis, extension of the aortic lesions, emergency and redo surgery were the only significant risk factors of mortality (P = 0.05). Cord ischemia was observed in 9 patients (21%): permanent paraplegia in 7 patients (16.2%) and transient medullar disturbance in 2 patients (4.6%). The occurrence of paraplegia was reduced, though not significantly, in group II (16%) vs group I (29%) and in patients with preoperative assessment of the cord vascularization (18% vs 38%). CONCLUSIONS: In our experience: 1) The risk of paraplegia is related to the extension and the type of the aortic lesions. 2) The preoperative study of the medullar vascularization and the use of extracorporeal circulation with deep hypothermia and sequential aortic unclamping, reduce the risk of severe cord ischemia, and 3) Occurrence of postoperative paraplegia depends on several factors and cannot be totally prevented by the surgical technique.


Subject(s)
Aortic Aneurysm, Abdominal/surgery , Aortic Aneurysm, Thoracic/surgery , Aortic Dissection/surgery , Intraoperative Complications/prevention & control , Ischemia/prevention & control , Paraplegia/prevention & control , Postoperative Complications/prevention & control , Spinal Cord/blood supply , Adult , Aged , Anastomosis, Surgical , Aortic Dissection/mortality , Aortic Aneurysm, Abdominal/mortality , Aortic Aneurysm, Thoracic/mortality , Arteries/surgery , Arteriosclerosis/mortality , Arteriosclerosis/surgery , Blood Vessel Prosthesis , Female , Hospital Mortality , Humans , Intraoperative Complications/mortality , Ischemia/mortality , Male , Marfan Syndrome/mortality , Marfan Syndrome/surgery , Middle Aged , Paraplegia/mortality , Postoperative Complications/mortality , Reoperation , Risk , Treatment Outcome
17.
Carcinogenesis ; 10(2): 405-6, 1989 Feb.
Article in English | MEDLINE | ID: mdl-2912592

ABSTRACT

The generation of superoxide and hydroxyl radicals is known to be implicated in the hydroxylation of 2'-deoxyguanosine (dG) at the C-8 position and of guanine base residues in DNA. It was also shown previously that in the presence of horseradish peroxidase, hydrogen peroxide and Fe3+ - EDTA complex, diethylstilbestrol (DES) induces single strand breaks in DNA, caused by the production of superoxide anion (O2-) and hydroxyl (OH.) radicals. By means of high-pressure liquid chromatography and electrochemical detection a strong indication is adduced that dG is oxidized to 8-hydroxy-2'-deoxyguanosine during peroxidative in vitro metabolism of DES, which might be at the basis of DES induced cell transformation.


Subject(s)
Deoxyguanosine/analogs & derivatives , Diethylstilbestrol/metabolism , Peroxides/metabolism , 8-Hydroxy-2'-Deoxyguanosine , Chromatography, High Pressure Liquid , Deoxyguanosine/metabolism
19.
Z Lebensm Unters Forsch ; 186(1): 25-8, 1988 Jan.
Article in English | MEDLINE | ID: mdl-3354263

ABSTRACT

A simple and rapid method is described for the extraction, derivatization and subsequent determination by means of high pressure liquid chromatography of putrescine, cadaverine, histamine, spermidine and spermine as their 5-dimethylaminonaphthalene-1-sulphonyl derivatives. The amines are extracted from the fish material by an aqueous trichloroacetic acid solution and derivatized by means of 5-dimethylaminonaphthalene-1-sulphonylchloride (dansyl chloride). The reaction mixture is then injected on a RP-8 column using gradient elution to separate the amine derivatives. Use of the method results in a considerable saving with respect to both time and costs.


Subject(s)
Cadaverine/analysis , Diamines/analysis , Histamine/analysis , Meat/analysis , Putrescine/analysis , Spermidine/analysis , Spermine/analysis , Animals , Chromatography, High Pressure Liquid/methods , Dansyl Compounds , Fishes , Indicators and Reagents
20.
Clin Chim Acta ; 165(1): 21-5, 1987 May 29.
Article in English | MEDLINE | ID: mdl-3301076

ABSTRACT

In 16 patients with a renal allograft the activity concentrations of aspartate aminotransferase and alanine aminotransferase and the percentage stimulation of both enzymes were investigated. After the transplantation the patients received prednisone and cyclosporine A as immunosuppressive therapy, while exactly 3 months after the date of transplantation prednisone and azathioprine were given as immunosuppressives. In the first period, the percentage increase of the activity concentration of aspartate aminotransferase and alanine aminotransferase upon supplementation of pyridoxal-5'-phosphate in vitro were similar to that of healthy individuals. In the second period, however, the percentage increase of the activity concentration of alanine aminotransferase was much higher than that of aspartate aminotransferase. Cyclosporine A given during a period of about 400 days did not influence the percentage increase of both enzymes. It is concluded that the high stimulation of alanine aminotransferase in the second period depends on the presence of azathioprine or its metabolites in serum.


Subject(s)
Apoenzymes/blood , Apoproteins/blood , Azathioprine/adverse effects , Cyclosporins/adverse effects , Kidney Transplantation , Transaminases/blood , Adult , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Creatinine/blood , Female , Humans , Male , Middle Aged , Prednisone/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...